Which Patients With MASH Are Candidates for Drug Treatment?

Answer in brief: Drug therapy for MASH is aimed primarily at patients with non-cirrhotic disease and clinically significant fibrosis, especially F2–F3, after fibrosis risk has been confirmed with appropriate noninvasive testing and/or biopsy when necessary. As of 2026, resmetirom and semaglutide have disease-specific roles in selected adults with MASH and moderate-to-advanced fibrosis. Lifestyle treatment and aggressive cardiovascular/metabolic risk reduction remain foundational for every patient.

Key clinical points

Do not treat hepatic steatosis alone as an indication for MASH drug therapy.
Confirm clinically significant fibrosis before disease-specific pharmacotherapy.
Resmetirom is used in non-cirrhotic MASH with F2–F3 fibrosis.
AASLD’s 2025 update addresses semaglutide in selected F2–F3 MASH.

Who is the target population

The clinically important transition is from steatosis without advanced fibrosis to MASH with fibrosis that materially increases the risk of cirrhosis and liver-related outcomes. Patients with F2–F3 fibrosis are therefore the key population for current disease-specific drug therapy.

Resmetirom

Resmetirom, a thyroid hormone receptor-β agonist, became the first FDA-approved disease-specific therapy for non-cirrhotic MASH with moderate-to-advanced fibrosis. AASLD updated its guidance in 2024 to address patient selection, monitoring and use. It should not be extrapolated to decompensated cirrhosis.

Semaglutide

AASLD issued a November 2025 update addressing semaglutide therapy for MASH with F2–F3 fibrosis. Its metabolic benefits are especially relevant in patients with obesity or type 2 diabetes, but patient selection and monitoring should follow current labeling and liver guidance rather than assuming that any patient with fatty liver qualifies.

Foundation remains metabolic care

Weight reduction, exercise, diabetes treatment, lipid management, blood-pressure control and avoidance of harmful alcohol exposure reduce overall risk. Cardiovascular disease remains a major cause of morbidity and mortality in MASLD, so a liver-only approach is incomplete.

Practical approach

1. Confirm MASH rather than steatosis alone.

2. Establish fibrosis stage, focusing on F2–F3 non-cirrhotic disease.

3. Optimize weight, diabetes, lipid and cardiovascular care.

4. Consider current disease-specific pharmacotherapy using up-to-date AASLD guidance and labeling.

Common errors to avoid

Prescribing MASH drugs for steatosis without confirming clinically significant fibrosis.
Focusing on liver therapy while neglecting cardiovascular risk.

Trainee takeaway

Drug therapy for MASH is aimed primarily at patients with non-cirrhotic disease and clinically significant fibrosis, especially F2–F3, after fibrosis risk has been confirmed with appropriate noninvasive testing and/or biopsy when necessary. The examination question is usually less about memorizing one cutoff than recognizing which finding changes the next clinical decision.

Relevant free books by Dr. Alan B. R. Thomson

Thomson ABR. Guideline-Based Management in Hepatology. CAPstone Academic Publishers; 2015. ISBN 978-1502928078.
Thomson ABR. Clinical Pharmacology, Physiology and Pathophysiology: Gastroenterology, Hepatology, and Pancreaticobiliary Disorders. CAPstone Academic Publishers; 2024. ISBN 979-8323955770.

Free downloads: https://giandhepatology.com/free-medical-books-on-gastroenterology-and-hepatology

Frequently asked questions

Should a patient with simple steatosis receive resmetirom?

No. Current disease-specific therapy targets selected patients with non-cirrhotic MASH and significant fibrosis.

Does cirrhosis change the treatment strategy?

Yes. Current approved MASH therapies are not simply extended into decompensated cirrhosis; cirrhosis requires portal-hypertension, HCC and transplant-risk management.

References

1. Thomson ABR. Guideline-Based Management in Hepatology. CAPstone Academic Publishers; 2015. ISBN 978-1502928078.

2. Thomson ABR. Clinical Pharmacology, Physiology and Pathophysiology: Gastroenterology, Hepatology, and Pancreaticobiliary Disorders. CAPstone Academic Publishers; 2024. ISBN 979-8323955770.

3. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797-1835. doi:10.1097/HEP.0000000000000323.

4. AASLD. Resmetirom Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease: October 2024 Updates to AASLD Practice Guidance.

5. AASLD. Semaglutide Therapy for Metabolic Dysfunction-Associated Steatohepatitis: November 2025 Updates to AASLD Practice Guidance.

Editorial note: This educational article synthesizes Dr. Thomson’s teaching framework with current society guidance. Recommendations should be checked against the latest guideline, local formulary, regulatory labeling and the individual clinical context before patient-specific use.